Sonia Solomon1, Adriana Colovai2, Marcela Del Rio1, Nicole Hayde3. 1. Children's Hospital at Montefiore, Bronx, NY, USA. 2. Montefiore Einstein Center for Transplantation, Bronx, NY, USA. 3. Children's Hospital at Montefiore, Bronx, NY, USA. nhayde@montefiore.org.
Abstract
BACKGROUND: Donor-specific antibody (DSA) is a risk factor for antibody-mediated rejection and shortened graft survival. We investigated the role of intrapatient variability in tacrolimus trough levels on graft outcomes (i.e., de novo DSA, rejection, graft loss) in pediatric renal transplant recipients. METHODS: This was a single-center retrospective study which included 38 pediatric renal transplant recipients. Intrapatient tacrolimus variability was defined using the coefficient of variation (CV; SD/Mean × 100) for all levels obtained after 3 months post-transplant. CV cut-points of 30%, 40%, and 50% were used in the analyses. RESULTS: The median CV 43.1% (35.0%, 58.6%). Out of 38 patients, 19 (50%) developed de novo DSA. In the logistic regression model, after adjusting for age, rejection history, maintenance immunosuppression, and CV, for every 10% increase in tacrolimus variability, the odds of developing de novo DSA increased by 53% (p = 0.048, CI 1.0005, 1.11). Age at transplant was also an independent risk factor for DSA development; every 1 year increase in age was associated with a 31% increase in the odds of developing DSA (p = 0.03, CI 1.03, 1.67). At a CV cut-point ≥ 30%, higher tacrolimus variability was associated with an increased incidence of allograft rejection (0% vs 42%, < 30 and ≥ 30% respectively, p = 0.07). As there were few graft loss events (n = 4) in our study population, an association could not be determined between tacrolimus variability and graft loss. CONCLUSION: Tacrolimus variability and age at transplant were identified as independent risk factors for de novo DSA development. There was an association between tacrolimus variability and rejection in pediatric renal transplant recipients. Adding the assessment of tacrolimus variability to current monitoring methods may be an important step towards improving graft outcomes.
BACKGROUND:Donor-specific antibody (DSA) is a risk factor for antibody-mediated rejection and shortened graft survival. We investigated the role of intrapatient variability in tacrolimus trough levels on graft outcomes (i.e., de novo DSA, rejection, graft loss) in pediatric renal transplant recipients. METHODS: This was a single-center retrospective study which included 38 pediatric renal transplant recipients. Intrapatient tacrolimus variability was defined using the coefficient of variation (CV; SD/Mean × 100) for all levels obtained after 3 months post-transplant. CV cut-points of 30%, 40%, and 50% were used in the analyses. RESULTS: The median CV 43.1% (35.0%, 58.6%). Out of 38 patients, 19 (50%) developed de novo DSA. In the logistic regression model, after adjusting for age, rejection history, maintenance immunosuppression, and CV, for every 10% increase in tacrolimus variability, the odds of developing de novo DSA increased by 53% (p = 0.048, CI 1.0005, 1.11). Age at transplant was also an independent risk factor for DSA development; every 1 year increase in age was associated with a 31% increase in the odds of developing DSA (p = 0.03, CI 1.03, 1.67). At a CV cut-point ≥ 30%, higher tacrolimus variability was associated with an increased incidence of allograft rejection (0% vs 42%, < 30 and ≥ 30% respectively, p = 0.07). As there were few graft loss events (n = 4) in our study population, an association could not be determined between tacrolimus variability and graft loss. CONCLUSION:Tacrolimus variability and age at transplant were identified as independent risk factors for de novo DSA development. There was an association between tacrolimus variability and rejection in pediatric renal transplant recipients. Adding the assessment of tacrolimus variability to current monitoring methods may be an important step towards improving graft outcomes.
Authors: Kyle J Van Arendonk; Brian J Boyarsky; Babak J Orandi; Nathan T James; Jodi M Smith; Paul M Colombani; Dorry L Segev Journal: Pediatrics Date: 2014-03-10 Impact factor: 7.124
Authors: Donald E Hricik; Richard N Formica; Peter Nickerson; David Rush; Robert L Fairchild; Emilio D Poggio; Ian W Gibson; Chris Wiebe; Kathryn Tinckam; Suphamai Bunnapradist; Milagros Samaniego-Picota; Daniel C Brennan; Bernd Schröppel; Osama Gaber; Brian Armstrong; David Ikle; Helena Diop; Nancy D Bridges; Peter S Heeger Journal: J Am Soc Nephrol Date: 2015-04-29 Impact factor: 10.121
Authors: F Ginevri; A Nocera; P Comoli; A Innocente; M Cioni; A Parodi; I Fontana; A Magnasco; A Nocco; A Tagliamacco; A Sementa; P Ceriolo; L Ghio; M Zecca; M Cardillo; G Garibotto; G M Ghiggeri; F Poli Journal: Am J Transplant Date: 2012-09-07 Impact factor: 8.086
Authors: Saskia N de Wildt; Ron H N van Schaik; Offie P Soldin; Steve J Soldin; Parvaneh Yazdani Brojeni; Ilse P van der Heiden; Chris Parshuram; Irena Nulman; Gideon Koren Journal: Eur J Clin Pharmacol Date: 2011-06-23 Impact factor: 2.953
Authors: Kim H Piburn; Vaka K Sigurjonsdottir; Olafur S Indridason; Lynn Maestretti; Mary Victoria Patton; Anne McGrath; Runolfur Palsson; Amy Gallo; Abanti Chaudhuri; Paul C Grimm Journal: Clin J Am Soc Nephrol Date: 2022-07-26 Impact factor: 10.614
Authors: Agnieszka Urzykowska; Barbara Piątosa; Urszula Grycuk; Grzegorz Kowalewski; Zbigniew Kułaga; Ryszard Grenda Journal: Children (Basel) Date: 2021-12-09